Apyx Medical arrived at its second-quarter print with a quiet inflection already underway. Both reportable segments - Surgical Aesthetics (Renuvion and the AYON Body Contouring System) and OEM (contract-manufactured surgical devices) - generated positive segment operating income for the first time on the same quarter. Surgical Aesthetics sales rose 28% to $12.4 million, OEM held positive territory on $1.5 million, and the operating loss narrowed to $1.8 million from $2.6 million. The result is a credible step toward the management's reaffirmed full-year outlook of $59.0–60.0 million in revenue, with both segments leaning into growth, and the company now reaching the moment where the GAAP loss is no longer a measure of the underlying business.
There is, however, a second story this quarter, and the company itself does not soft-pedal it. Operating cash use of $3.5 million in the quarter pushed first-half operating cash burn to $4.1 million, deepening from $1.9 million in the year-ago half on a smaller operating loss. Cash and cash equivalents closed at $27.6 million, down $4.1 million from year-end 2025. The drivers management names - the 2025 bonus payment in Q1 2026, inventory build for the expanded AYON and power-liposuction product portfolio, and working-capital absorption - are real, but they are the same drivers that produced an operating-cash print that, for the first time in several quarters, ran materially worse than the headline net loss. The investor question is whether the inventory build is a one-quarter timed event ahead of the power-liposuction launch, or the start of a working-capital expansion that stretches the run of the Perceptive term loan (12.0% all-in at quarter-end, $35.3 million outstanding).
Management has chosen to back its own answer with a third story. It reaffirmed fiscal 2026 total revenue guidance of $59.0–60.0 million - implying a second-half step-up of roughly 17–22% over the first half - Surgical Aesthetics guidance of $54.0–55.0 million, OEM of approximately $5.0 million, and total operating expenses of less than $45.0 million. Stock-based compensation in the first half ran $1.4 million versus $1.0 million the year prior, and was treated as the largest discretionary add-back. Adjusted EBITDA loss narrowed to $0.7 million in Q2 2026 from $2.0 million the year prior, a $1.3 million improvement, while GAAP net loss attributable to stockholders narrowed to $3.2 million from $3.8 million. Two segments, same quarter, both producing GAAP operating profit. The investment case is now a transition story measured in milestones - AYON commercialization, the power-liposuction handpiece ramp, the OEM runoff, the $52.4 million Surgical Aesthetics TTM revenue covenant for fiscal 2026, and the cash-flow trajectory into 2027.